---
title: "Meta-analysis addendum: Revised trial-level links between GFR slope and kidney failure"
id: "nature-0-addendum-a-meta-analysis-of-gfr-slope-as-a-surrogate-endpoint-for-kidney-failure"
canonical_url: "https://medichelpline.com/clinical-feed/nature-0-addendum-a-meta-analysis-of-gfr-slope-as-a-surrogate-endpoint-for-kidney-failure"
content_type: "clinical_feed_article"
specialty: "Nephrology"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04798-5"
published_at: "2026-11-16T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Meta-analysis addendum: Revised trial-level links between GFR slope and kidney failure
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-0-addendum-a-meta-analysis-of-gfr-slope-as-a-surrogate-endpoint-for-kidney-failure
- **Specialty:** [Nephrology](https://medichelpline.com/clinical-feed/nephrology.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04798-5)
- **Published At:** 2026-11-16T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The authors issued an addendum correcting the multi-arm trial designations used in their trial-level Bayesian meta-regression; the error involved shared-control specification for the AASK trial. - The analytic framework modelled the association between treatment effects on **GFR slope** and treatment effects on the clinical endpoint of **kidney failure**, accounting for correlated sampling errors in multi-arm trials with shared controls. - After re-running the meta-regression with the correct multi-arm designations, the summary estimates changed only in the hundredths place compared with the originally published results. - The revised trial-level outputs are presented in Figure 1 and Table 1 of the Addendum; the dataset used 66 studies and plotted study-level treatment effects as sized circles proportional to event counts. - The Addendum reports two fitted meta-regression lines: one for the 3-year total GFR slope (R2 = 0.95; slope = −0.35) and one for the chronic GFR slope (R2 = 0.55; slope = −0.33), with 95% Bayesian pointwise confidence bands around the regressions. - Outcomes counted as events included kidney failure with replacement therapy, estimated GFR <15 mL/min/1.73 m2, or doubling of serum creatinine, and triangle markers denote studies with treatment effects beyond plotted margins. - Circles in the plots were coloured by intervention class and scaled to the number of events; intervention categories listed in the Addendum include RASB, CCB, BP lowering, DPP-4, GLP-1, SGLT2 and others as in the original analysis. - The authors include members of the **CKD-EPI Clinical Trials Consortium** and multiple international nephrology centres; affiliations and full author list are provided in the Addendum. - The Addendum points readers to the corrected Figure 1 and Table 1 for trial-level association summaries and notes the underlying original article citation for full methods and context.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41591-026-04798-5#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Medicine](https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg) ](https://www.nature.com/nm) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-026-04798-5) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nm/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nm/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nm/news-and-comment) * [ Podcasts ](https://www.nature.com/nm/podcast) * [ Current issue ](https://www.nature.com/nm/current-issue) * [ Collections ](https://www.nature.com/nm/collections) * [Follow us on Facebook ](https://www.facebook.com/Nature-Medicine-193691346949/) * [Follow us on X ](https://twitter.com/naturemedicine) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nm/aims) * [ Journal Information ](https://www.nature.com/nm/journal-information) * [ Editors ](https://www.nature.com/nm/editors) * [ Journal Metrics ](https://www.nature.com/nm/journal-impact) * [ Research Cross-Journal Editorial Team ](https://www.nature.com/nm/research-cross-journal-editorial-team) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nm/reviews-cross-journal-editorial-team) * [ Statistical Advisory Panel ](https://www.nature.com/nm/statistics-advisory-panel) * [ Our publishing models ](https://www.nature.com/nm/our-publishing-models) * [ Editorial Values Statement ](https://www.nature.com/nm/editorial-values-statement) * [ Editorial Policies ](https://www.nature.com/nm/editorial-policies) * [ Content Types ](https://www.nature.com/nm/content) * [ Web Feeds ](https://www.nature.com/nm/web-feeds) * [ Contact ](https://www.nature.com/nm/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ Submission Guidelines ](https://www.nature.com/nm/submission-guidelines) * [ For Reviewers ](https://www.nature.com/nm/for-reviewers) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/nm/open-access-funding) * [Submit manuscript ](https://mts-nmed.nature.com/cgi-bin/main.plex) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) 1. [nature](https://www.nature.com/) 2. [nature medicine](https://www.nature.com/nm) 3. [addenda](https://www.nature.com/nm/articles?type=addendum) 4. article Addendum: A meta-analysis of GFR slope as a surrogate endpoint for kidney failure [ Download PDF ](https://www.nature.com/articles/s41591-026-04798-5.pdf) [ Download PDF ](https://www.nature.com/articles/s41591-026-04798-5.pdf) * Addendum * Published: 16 November 2026 # Addendum: A meta-analysis of GFR slope as a surrogate endpoint for kidney failure * [Lesley A. Inker](https://www.nature.com/articles/s41591-026-04798-5#auth-Lesley_A_-Inker-Aff1) [ORCID: orcid.org/0000-0003-2820-9482](https://orcid.org/0000-0003-2820-9482)[1](https://www.nature.com/articles/s41591-026-04798-5#Aff1), * [Willem Collier](https://www.nature.com/articles/s41591-026-04798-5#auth-Willem-Collier-Aff2)[2](https://www.nature.com/articles/s41591-026-04798-5#Aff2), * [Tom Greene](https://www.nature.com/articles/s41591-026-04798-5#auth-Tom-Greene-Aff2)[2](https://www.nature.com/articles/s41591-026-04798-5#Aff2), * [Shiyuan Miao](https://www.nature.com/articles/s41591-026-04798-5#auth-Shiyuan-Miao-Aff1)[1](https://www.nature.com/articles/s41591-026-04798-5#Aff1), * [Juhi Chaudhari](https://www.nature.com/articles/s41591-026-04798-5#auth-Juhi-Chaudhari-Aff1)[1](https://www.nature.com/articles/s41591-026-04798-5#Aff1), * [Gerald B. Appel](https://www.nature.com/articles/s41591-026-04798-5#auth-Gerald_B_-Appel-Aff3)[3](https://www.nature.com/articles/s41591-026-04798-5#Aff3), * [Sunil V. Badve](https://www.nature.com/articles/s41591-026-04798-5#auth-Sunil_V_-Badve-Aff4)[4](https://www.nature.com/articles/s41591-026-04798-5#Aff4), * [Fernando Caravaca-Fontán](https://www.nature.com/articles/s41591-026-04798-5#auth-Fernando-Caravaca_Font_n-Aff5) [ORCID: orcid.org/0000-0002-5830-9663](https://orcid.org/0000-0002-5830-9663)[5](https://www.nature.com/articles/s41591-026-04798-5#Aff5), * [Lucia Del Vecchio](https://www.nature.com/articles/s41591-026-04798-5#auth-Lucia-Vecchio-Aff6)[6](https://www.nature.com/articles/s41591-026-04798-5#Aff6), * [Jürgen Floege](https://www.nature.com/articles/s41591-026-04798-5#auth-J_rgen-Floege-Aff7)[7](https://www.nature.com/articles/s41591-026-04798-5#Aff7), * [Marian Goicoechea](https://www.nature.com/articles/s41591-026-04798-5#auth-Marian-Goicoechea-Aff8)[8](https://www.nature.com/articles/s41591-026-04798-5#Aff8), * [Benjamin Haaland](https://www.nature.com/articles/s41591-026-04798-5#auth-Benjamin-Haaland-Aff2)[2](https://www.nature.com/articles/s41591-026-04798-5#Aff2), * [William G. Herrington](https://www.nature.com/articles/s41591-026-04798-5#auth-William_G_-Herrington-Aff9)[9](https://www.nature.com/articles/s41591-026-04798-5#Aff9), * [Enyu Imai](https://www.nature.com/articles/s41591-026-04798-5#auth-Enyu-Imai-Aff10)[10](https://www.nature.com/articles/s41591-026-04798-5#Aff10), * [Tazeen H. Jafar](https://www.nature.com/articles/s41591-026-04798-5#auth-Tazeen_H_-Jafar-Aff11) [ORCID: orcid.org/0000-0001-7454-8376](https://orcid.org/0000-0001-7454-8376)[11](https://www.nature.com/articles/s41591-026-04798-5#Aff11), * [Julia B. Lewis](https://www.nature.com/articles/s41591-026-04798-5#auth-Julia_B_-Lewis-Aff12)[12](https://www.nature.com/articles/s41591-026-04798-5#Aff12), * [Philip K. T. Li](https://www.nature.com/articles/s41591-026-04798-5#auth-Philip_K__T_-Li-Aff13) [ORCID: orcid.org/0000-0001-9879-8388](https://orcid.org/0000-0001-9879-8388)[13](https://www.nature.com/articles/s41591-026-04798-5#Aff13), * [Bart D. Maes](https://www.nature.com/articles/s41591-026-04798-5#auth-Bart_D_-Maes-Aff14) [ORCID: orcid.org/0000-0001-5084-5130](https://orcid.org/0000-0001-5084-5130)[14](https://www.nature.com/articles/s41591-026-04798-5#Aff14), * [Brendon L. Neuen](https://www.nature.com/articles/s41591-026-04798-5#auth-Brendon_L_-Neuen-Aff4)[4](https://www.nature.com/articles/s41591-026-04798-5#Aff4), * [Ronald D. Perrone](https://www.nature.com/articles/s41591-026-04798-5#auth-Ronald_D_-Perrone-Aff1)[1](https://www.nature.com/articles/s41591-026-04798-5#Aff1), * [Giuseppe Remuzzi](https://www.nature.com/articles/s41591-026-04798-5#auth-Giuseppe-Remuzzi-Aff15) [ORCID: orcid.org/0000-0002-6194-3446](https://orcid.org/0000-0002-6194-3446)[15](https://www.nature.com/articles/s41591-026-04798-5#Aff15), * [Francesco P. Schena](https://www.nature.com/articles/s41591-026-04798-5#auth-Francesco_P_-Schena-Aff16)[16](https://www.nature.com/articles/s41591-026-04798-5#Aff16), * [Christoph Wanner](https://www.nature.com/articles/s41591-026-04798-5#auth-Christoph-Wanner-Aff17)[17](https://www.nature.com/articles/s41591-026-04798-5#Aff17), * [Jack F. M. Wetzels](https://www.nature.com/articles/s41591-026-04798-5#auth-Jack_F__M_-Wetzels-Aff18) [ORCID: orcid.org/0000-0002-0650-6921](https://orcid.org/0000-0002-0650-6921)[18](https://www.nature.com/articles/s41591-026-04798-5#Aff18), * [Mark Woodward](https://www.nature.com/articles/s41591-026-04798-5#auth-Mark-Woodward-Aff4-Aff19)[4](https://www.nature.com/articles/s41591-026-04798-5#Aff4),[19](https://www.nature.com/articles/s41591-026-04798-5#Aff19), * [Hiddo J. L. Heerspink](https://www.nature.com/articles/s41591-026-04798-5#auth-Hiddo_J__L_-Heerspink-Aff20)[20](https://www.nature.com/articles/s41591-026-04798-5#Aff20) & * [the CKD-EPI Clinical Trials Consortium](https://www.nature.com/articles/s41591-026-04798-5#group-1) Show authors [_Nature Medicine_](https://www.nature.com/nm) (2026) [Cite this article](https://www.nature.com/articles/s41591-026-04798-5#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) The [Original Article](https://doi.org/10.1038/s41591-023-02418-0) was published on 17 June 2023 Addendum to: _Nature Medicine_ , published online 17 June 2023. In the trial-level Bayesian meta-regression analysis that quantified the association between treatment effects on the GFR slope and treatment effects on clinical endpoints across randomized controlled trials, we accounted for the correlated sampling errors in multi-arm clinical trials with shared control groups[1](https://www.nature.com/articles/s41591-026-04798-5#ref-CR1 "Inker, L. A. et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat. Med. 29, 1867–1876 \(2023\)."). In the original publication, we had incorrectly stipulated the shared control groups in the African American Study of Kidney Disease (AASK)[2](https://www.nature.com/articles/s41591-026-04798-5#ref-CR2 "Wright, J. T. Jr. et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288, 2421–2431 \(2002\)."). We repeated the meta-regression with the correct designation of the multi-arm trials, and the summary results differed in the hundredths place compared to published results. The updated trial-level association summaries are shown in Fig. [1](https://www.nature.com/articles/s41591-026-04798-5#Fig1) and Table [1](https://www.nature.com/articles/s41591-026-04798-5#Tab1) in this Addendum. **Fig. 1: Trial-level analyses for the association between treatment effects on GFR slope and treatment effects on the clinical endpoint.** ![Two bubble plots compare treatment effects on GFR slope with treatment effects on clinical endpoint. Each plot includes 66 studies across multiple treatment categories, with 95% confidence intervals around the fitted lines. Both fitted lines decline: thus, greater treatment effects on GFR slope correspond to lower hazard ratios for the clinical endpoint. The association is tighter for the 3-year total slope than for the chronic slope, with R squared for the total GFR slope being 0.95 and that for chronic GFR slope being 0.55. Each plot includes 66 studies across multiple treatment categories, with 95% confidence intervals around the fitted lines. The meta-regression slopes are minus 0.35 and minus 0.33, respectively.](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-026-04798-5/MediaObjects/41591_2026_4798_Fig1_HTML.png) [Full size image](https://www.nature.com/articles/s41591-026-04798-5/figures/1) Circles represent separate studies with the size of the circle proportional to the number of events (kidney failure with replacement therapy, GFR <15 mL/min per 1.73 m2, or doubling of serum creatinine). The colors of circles indicate intervention types. The black line is the line of regression through the studies. Blue lines are the 95% pointwise Bayesian confidence bands. Triangles indicate studies where the estimated treatment effects are beyond the margins. RASB, renin angiotensin system blockers; CCB, calcium channel blocker; BP, blood pressure; DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide-1, RMSE, root mean squared error; SGLT2, sodium glucose cotransporter. **Table 1 Trial-level analysis by subgroups** [ Full size table](https://www.nature.com/articles/s41591-026-04798-5/tables/1) ### Explore related subjects Discover the latest articles and news in related subjects. * [Chronic kidney disease](https://www.nature.com/subjects/chronic-kidney-disease) * [Predictive markers](https://www.nature.com/subjects/predictive-markers) ## References 1. Inker, L. A. et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. _Nat. Med._ **29** , 1867–1876 (2023). [Article](https://doi.org/10.1038%2Fs41591-023-02418-0) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37330614) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC13037386) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20meta-analysis%20of%20GFR%20slope%20as%20a%20surrogate%20endpoint%20for%20kidney%20failure&journal=Nat.%20Med.&doi=10.1038%2Fs41591-023-02418-0&volume=29&pages=1867-1876&publication_year=2023&author=Inker%2CLA) 2. Wright, J. T. Jr. et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. _JAMA_ **288** , 2421–2431 (2002). [Article](https://doi.org/10.1001%2Fjama.288.19.2421) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12435255) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effect%20of%20blood%20pressure%20lowering%20and%20antihypertensive%20drug%20class%20on%20progression%20of%20hypertensive%20kidney%20disease%3A%20results%20from%20the%20AASK%20trial&journal=JAMA&doi=10.1001%2Fjama.288.19.2421&volume=288&pages=2421-2431&publication_year=2002&author=Wright%2CJT) [Download references](https://citation-needed.springer.com/v2/references/10.1038/s41591-026-04798-5?format=refman&flavour=references) ## Author information ### Authors and Affiliations 1. Division of Nephrology, Tufts Medical Center, Boston, MA, USA Lesley A. Inker, Shiyuan Miao, Juhi Chaudhari & Ronald D. Perrone 2. Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA Willem Collier, Tom Greene & Benjamin Haaland 3. Division of Nephrology, Columbia University Medical Center and the New York Presbyterian Hospital, New York, NY, USA Gerald B. Appel & Pietro Canetta 4. George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia Sunil V. Badve, Brendon L. Neuen, Mark Woodward, John Chalmers, Bruce Neal, Vlado Perkovic, David Johnson & Meg Jardine 5. Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain Fernando Caravaca-Fontán, Hernando Trujillo, Teresa Cavero & Angel Sevillano 6. Department of Nephrology and Dialysis, Sant’Anna Hospital, ASST Lariana, Como, Italy Lucia Del Vecchio 7. Division of Nephrology, RWTH Aachen University, Aachen, Germany Jürgen Floege & Thomas Rauen 8. Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain Marian Goicoechea, Eduardo Verde, Ursula Verdalles & David Arroyo 9. Medical Research Council Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK William G. Herrington 10. Nakayamadera Imai Clinic, Takarazuka, Japan Enyu Imai 11. Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore Tazeen H. Jafar 12. Division of Nephrology, Vanderbilt University Medical Center, Nashville, TN, USA Julia B. Lewis & Jamie Dwyer 13. Division of Nephrology, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China Philip K. T. Li, Kai-Ming Chow, Cheuk-Chun Szeto & Chi-Bon Leung 14. Department of Nephrology, AZ Delta, Roeselare, Belgium Bart D. Maes 15. Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy Giuseppe Remuzzi, Piero Ruggenenti, Annalisa Perna & Fabiola Carrara 16. Renal, Dialysis and Transplant Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy Francesco P. Schena & Carlo Manno 17. Renal Research Unit, Comprehensive Heart Failure Center, Department of Clinical Research and Epidemiology, University of Würzburg, Würzburg, Germany Christoph Wanner 18. Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands Jack F. M. Wetzels 19. George Institute for Global Health, School of Public Health, Imperial College London, London, UK Mark Woodward 20. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands Hiddo J. L. Heerspink 21. Denver Health, Denver, CO, USA Raymond O. Estacio, Rebecca Hanratty, Di Xie & Fan Fan Hou 22. Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada Brendan Barrett 23. Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA, USA Kenneth W. Mahaffey 24. Boehringer Ingelheim International, Ingelheim, Germany Maximilian von Eynatten 25. Section of Nephrology, University of Chicago School of Medicine, Chicago, IL, USA Arlene Chapman 26. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA Vicente Torres 27. Department of Medicine, Division of Nephrology and Hypertension, University of Kansas Medical Center, Kansas City, KS, USA Alan Yu 28. Division of Diseases and Hypertension, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, USA Godela Brosnahan 29. Department of Nephrology Dialysis and Renal Transplantation, Alessandro Manzoni Hospital, Lecco, Italy Thierry Hannedouche, Giuseppe Maschio, Francesco Locatelli, Simeone Andrulli, Claudio Pozzi & Donatella Casartelli 30. Cleveland Clinic Foundation, Cleveland, OH, USA Marc A. Pohl 31. Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel Itamar Raz 32. Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA, USA Lawrence G. Hunsicker 33. Department of Nephrology, Heilig Hartziekenhuis Roeselare-Menen, Roeselare, Belgium An Vanacker 34.
## Related Clinical Research

- [Global and Regional Trends in Chronic Kidney Disease Incidence, 1992–2021, with Projections to 2031](https://medichelpline.com/clinical-feed/plos-one-20-temporal-trends-in-the-incidence-of-chronic-kidney-disease-from-1992-to-2021-an.md)
- [Risk Factors for Progressive Cardiorenal Syndrome in CKD: Findings from the CRIC Cohort](https://medichelpline.com/clinical-feed/medrxiv-1-risk-factors-for-progressive-cardiorenal-syndrome-events-in-patients-with.md)
- [Prevalence, risk factors, and renoprotective treatment gaps in chronic kidney disease among tertia](https://medichelpline.com/clinical-feed/bmj-open-9-prevalence-risk-factors-and-renoprotective-treatment-of-chronic-kidney-disease.md)
- [Cardiovascular risk and mortality after statin initiation: achieved LDL and non‑HDL levels in a 3‑](https://medichelpline.com/clinical-feed/plos-medicine-0-risk-of-cardiovascular-events-and-mortality-associated-with-ldl-and-non-hdl.md)
- [ZEUS trial: IL-6 blocker ziltivekimab lowered inflammation but did not cut major CV events](https://medichelpline.com/clinical-feed/aha-news-1-researchers-say-inflammation-as-a-treatment-target-still-important-despite.md)

## Navigation
- [← Back to Nephrology Feed](https://medichelpline.com/clinical-feed/nephrology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.